White House and Congress Propose AI Legislation as FDA Continues to Act as AI Regulatory Gatekeeper
BioSpace
NOVEMBER 21, 2023
As artificial intelligence (AI) continues to be adopted by the pharmaceutical industry, regulatory bodies in the United States and other countries are evolving to tackle challenges within the industry. These include data privacy, bias, accuracy, access, as well as appropriate uses of AI and incorporating checks and balances into its usage. On October 30, the White House’s Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence (EO) instructed agencies
Let's personalize your content